(109 days)
Not Found
No
The document describes a laser system for photocoagulation and does not mention any AI or ML capabilities. The focus is on the laser delivery and multi-spot treatment options.
Yes
The device is described as an "ophthalmic surgical laser intended for use in the photocoagulation of ocular tissues in treatment of diseases of the eye," indicating it is used to treat medical conditions.
No.
The device is described as a "multi-wavelength ophthalmic surgical laser intended for use in the photocoagulation of ocular tissues in treatment of diseases of the eye", indicating its therapeutic rather than diagnostic function.
No
The device description explicitly states it is a "multi-wavelength ophthalmic surgical laser" and includes a "modified laser slit lamp," indicating it is a hardware device that delivers energy for photocoagulation.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use clearly states that the device is for "single-spot laser photocoagulation of ocular tissues" and "multispot retinal, panretinal, focal and grid photocoagulation of ocular tissues." This describes a therapeutic intervention performed directly on the patient's eye.
- Device Description: The description details a "multi-wavelength ophthalmic surgical laser" that delivers energy via "transpupillary delivery or intraocular endoprobe delivery." This further confirms its use as a surgical tool for treating eye conditions.
- Lack of IVD Characteristics: There is no mention of the device being used to examine specimens (like blood, urine, or tissue samples) outside of the body to provide information for diagnosis, monitoring, or screening.
IVD devices are used to perform tests on samples taken from the body to provide information about a person's health. This device is a surgical laser used to treat conditions directly on the patient's eye.
N/A
Intended Use / Indications for Use
The VISULAS Trion Laser System is intended for use in single-spot laser photocoagulation of ocular tissues for the treatment of diseases of the eye, such as:
- Photocoagulation of the retina .
- t Trabeculoplasty for treatment of glaucoma
- . Iridotomy for treatment of glaucoma.
The VISULAS Trion Laser System with the VITE option is intended for use in multispot retinal, panretinal, focal and grid photocoagulation of ocular tissues in the treatment of diseases of the eye including:
- Proliferative and nonproliferative diabetic retinopathy .
- . Macular edema
- . Branch and central retinal vein occlusion
- Lattice degeneration .
- . Retinal tears and detachments
- Choroidal neovascularization associated with wet age-related macular . degeneration.
Product codes
GEX, HQF
Device Description
The VISULAS Trion Laser System with the VITE option is a multi-wavelength ophthalmic surgical laser intended for use in the photocoagulation of ocular tissues in treatment of diseases of the eye.
Similar to the predicate device, the VISULAS Trion Laser System (K072514) laser, energy for the proposed device is delivered via transpupillary delivery or intraocular endoprobe delivery.
The VISULAS Trion Laser System with the VITE option includes a modified laser slit lamp (LSL) that features a multi-spot treatment cascade delivery option. The modified LSL is identical to the LSL offered with the predicate device, the VISULAS 532s Laser System with the VITE option (K100035), also manufactured by Carl Zeiss Meditec.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
ocular tissues (eye)
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
The VISULAS Trion Laser System with VITE option has been designed and tested to applicable standards including software, functionality, electrical and electromagnetic compatibility. The determination of substantial equivalence is based on the comparison between the results of performance data conducted using the VISULAS Trion with the VITE option and the predicate devices. These results demonstrate the ability of the proposed device to produce photocoagulation of ocular tissues that is comparable to the photocoagulation produced by the predicate devices.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
K072514, K100035, K043486, K081744, K091666, K092621
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 886.4390 Ophthalmic laser.
(a)
Identification. An ophthalmic laser is an AC-powered device intended to coagulate or cut tissue of the eye, orbit, or surrounding skin by a laser beam.(b)
Classification. Class II.
0
4.0 510(K) SUMMARY
K 103056
This 510(k) summary of safety and effectiveness information is being submitted in accordance with the requirements of 21 CFR 807.92(a). FEB - 1 2011
4.1 SUBMITTER'S NAME, ADDRESS, TELEPHONE NUMBER, CONTACT PERSON, AND DATE SUMMARY PREPARED
| a. | Applicant: | Carl Zeiss Meditec AG
Goeschwitzer Strasse 51-52
7740 Jena
Germany |
|----|------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| b. | Contact Person: | Judith A. Brimacombe, MA
Director, Clinical/Regulatory Affairs
Carl Zeiss Meditec, Inc.
5160 Hacienda Drive
Dublin, CA 94568
USA
j.brimacombe@meditec.zeiss.com
Tel: (925) 557-4616
Fax: (925) 557-4259 |
| c. | Date Summary Prepared: | December 21, 2010 |
4.2 DEVICE NAME, CLASSIFICATION AND ESTABLISHMENT REGISTRATION
| a. | Trade/Proprietary Name: | VISULAS Trion Laser System with the VITE option |
|---|---|---|
| b. | Common/Usual Name: | Ophthalmic surgical laser |
| c. | Classification Name: | Laser instrument, surgical, powered |
| d. | Classification Code(s): | GEX, 21 CFR §878.4810 |
| e. | Reviewing Panel: | General and Plastic Surgery Devices |
| f. | Establishment Registration #: | 9615030 |
1
| PREDICATE DEVICE | MANUFACTURER | 510(k) CLEARANCE NUMBER | CLEARANCE DATE |
|---|---|---|---|
| VISULAS Trion Laser | |||
| System | Carl Zeiss Meditec | K072514 | September 21, 2007 |
| VISULAS 532s Laser | |||
| System with the VITE option | Carl Zeiss Meditec | K100035 | March 17, 2010 |
| PASCAL Photocoagulator | OptiMedica | ||
| Corporation | K043486, | ||
| K081744, | |||
| K091666, | |||
| K092621 | March 3, 2005, | ||
| September 9, 2008, | |||
| July 15, 2009, | |||
| September 25, 2009 |
4.3 PREDICATE DEVICE INFORMATION
4.4 DEVICE DESCRIPTION
The VISULAS Trion Laser System with the VITE option is a multi-wavelength ophthalmic surgical laser intended for use in the photocoagulation of ocular tissues in treatment of diseases of the eye.
Similar to the predicate device, the VISULAS Trion Laser System (K072514) laser, energy for the proposed device is delivered via transpupillary delivery or intraocular endoprobe delivery.
The VISULAS Trion Laser System with the VITE option includes a modified laser slit lamp (LSL) that features a multi-spot treatment cascade delivery option. The modified LSL is identical to the LSL offered with the predicate device, the VISULAS 532s Laser System with the VITE option (K100035), also manufactured by Carl Zeiss Meditec.
4.5 STATEMENT OF INTENDED USE
The VISULAS Trion Laser System is intended for use in single-spot laser photocoagulation of ocular tissues for the treatment of diseases of the eye, such as:
- . Photocoagulation of the retina
- Trabeculoplasty for treatment of glaucoma .
- . Iridotomy for treatment of glaucoma.
The VISULAS Trion Laser System with the VITE option is intended for use in multi-spot retinal, panretinal, focal and grid photocoagulation of ocular tissues in the treatment of diseases of the eye including:
- Proliferative and nonproliferative diabetic retinopathy .
- � Macular edema
- . Branch and central retinal vein occlusion
- . Lattice degeneration
- . Retinal tears and detachments
- Choroidal neovascularization associated with wet age-related macular degeneration. .
2
4.6 TECHNOLOGICAL CHARACTERISTICS COMPARISON
The VISULAS Trion Laser System with the VITE option has the same operating characteristics and is substantially equivalent to the predicate VISULAS Trion Laser System (K072514), also manufactured by Carl Zeiss Meditec AG. Both the predicate and proposed devices deliver laser energy via a Laser Slit Lamp (LSL), the Laser Indirect Ophthalmoscope LIO Trion (for transpupillary delivery) or the endoprobe (for intraocular delivery).
Substantial equivalence is also drawn to the previously cleared VISULAS 532s Laser System with the VITE option (K100035) which incorporates the same Laser Slit Lamp (LSL) that offers the same multi-spot treatment cascade functionality as the proposed device. The Pascal Photocoagulator (K043486, K081744, K091666, K092621) achieves similar multispot delivery in the same manner as both the proposed and predicate VISULAS Trion and VISULAS 532s with VITE option devices (K072514 and K100035).
4.7 BRIEF SUMMARY OF NONCLINICAL TESTS & RESULTS
The VISULAS Trion Laser System with VITE option has been designed and tested to applicable standards including software, functionality, electrical and electromagnetic compatibility. The determination of substantial equivalence is based on the comparison between the results of performance data conducted using the VISULAS Trion with the VITE option and the predicate devices. These results demonstrate the ability of the proposed device to produce photocoagulation of ocular tissues that is comparable to the photocoagulation produced by the predicate devices.
4.8 CONCLUSION
The VISULAS Trion Laser System with the VITE option is substantially equivalent to the predicate devices, the Laser Systems VISULAS Trion (K072514), VISULAS 532s with option VITE (K100035) and the Pascal Photocoagulator (K043486, K081744, K091666, K092621).
3
Image /page/3/Picture/1 description: The image shows the logo for the Department of Health & Human Services USA. The logo consists of a stylized eagle with three lines representing its wings, and the text "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" arranged in a circular pattern around the eagle. The logo is black and white.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Room -WO66-G609 Silver Spring, MD 20993-0002
Carl Zeiss Meditec AG % Carl Zeiss Meditec, Inc. Judith A. Brimacombe. MA Director, Clinical/Regulatory Affairs 5160 Hacienda Drive Dublin, California 94568
FFB - 1 201
Rc: K103056
Trade/Device Name: VISULAS Trion Laser System with the VITE Option Regulation Number: 21 CFR 886.4390 Regulation Name: Ophthalmic laser Regulatory Class: Class II Product Code: HQF Dated: December 31, 2010 Received: January 03, 2011
Dear Ms. Brimacombe:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indicetions for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, inting of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
4
Page 2 – Judith A. Brimacombe. MA
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (2) CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 100-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm1178001/pm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.
Sincerely yours,
Mark N. Melkerson Director Division of Surgical, Orthopedic And Restorative Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
5
510(k) Number (if known): K103056
Device Name(s): VISULAS Trion Laser System with the VITE option
Indications for Use:
The VISULAS Trion Laser System is intended for use in single-spot laser photocoagulation of ocular tissues for the treatment of diseases of the eye, such as:
- Photocoagulation of the retina .
- t Trabeculoplasty for treatment of glaucoma
- . Iridotomy for treatment of glaucoma.
The VISULAS Trion Laser System with the VITE option is intended for use in multispot retinal, panretinal, focal and grid photocoagulation of ocular tissues in the treatment of diseases of the eye including:
- Proliferative and nonproliferative diabetic retinopathy .
- . Macular edema
- . Branch and central retinal vein occlusion
- Lattice degeneration .
- . Retinal tears and detachments
- Choroidal neovascularization associated with wet age-related macular . degeneration.
Prescription Use X (Part 21 CFR 801 Subpart D) AND/OR
Over-The-Counter Use (21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Page 1 = of of = 1 =
$\frac{Nilpotent}{ (Division) of \mathbb{R}^m}$ for $n \times n$
(Division Sign-Off) Division of Surgical, Orthopedic, and Restorative Devices
510(k) Number K103056